HIV infection and aging

AIDS Reviews

Volumn 12, Issue 4, 2010, Pages 218-230

  Blanco, José R ^a   Caro, Ana M ^b   Pérez Cachafeiro, Santiago ^c   Gutiérrez, Félix ^d   Iribarren, José A ^e   González García, Juan ^f   Ferrando Martínez, Sara ^g   Navarro, Gema ^h   Moreno, Santiago ⁱ  

^a HOSPITAL SAN PEDRO   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL MONTECELO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h Hospital Universitari Parc Taulí   (Spain)

ⁱ UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Aging; AIDS; Elderly; Frailty; HIV

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR; MARAVIROC; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; AGING; BODY BUILD; BONE DISEASE; CANCER RISK; CARDIOVASCULAR DISEASE; COMORBIDITY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RISK; INNATE IMMUNITY; INTESTINE ABSORPTION; KIDNEY CLEARANCE; KIDNEY DISEASE; LIFE EXPECTANCY; LIVER METABOLISM; LUNG DISEASE; MASS SCREENING; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHARMACOGENETICS; REVIEW; SENESCENCE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79955716442     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1-19.
2. Nguyen N, Holodniy M. HIV infection in the elderly. Clin Interv Aging. 2008;3:453-72.
3. HIV/AIDS surveillance in Europe 2008. http://www.euro.who.int/-data/ assets/pdf-file/0006/78081/E93034 pdf [accessed Feb 2, 2010].
4. Viard J, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in HIV-infected patients receiving highly active antiretroviral therapy-evidence from the EuroSIDA study. J Infect Dis. 2001;183:1290-4. (Pubitemid 32281572)
5. Perez J, Moore R. Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort. Clin Infect Dis. 2003;36:212-8. (Pubitemid 36143421)
6. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004;18:2029-38.
7. Tumbarello M, Rabagliati R, de Gaetano DK, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004;4:46.
8. Antón E, Sala M, Mallolas J, et al. Estudio de una serie clínica de pariertes infectados por el VIH mayores de 50 años. [Study of a clinical series of patients infected with HIV and aged more than 50]. Enferm Infecc Microbiol Clin. 2005;23:145-8.
9. Vallecillo G, Knobel H, Guelar A, et al. Evolución de una cohorte de pacientes mayores de 60 años infectados por el VIH tratados con tratamiento antirretroviral de gran actividad. [Evolution of a cohort of patients HIV infected treated with HAART]. Enferm lnfecc Microbiol Clin. 2005;23:390-1.
10. Nogueras M, Navarro G, Antón E, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis. 2006;6:159.
11. Orlando G, Meraviglia P, Cordier L, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7:549-57. (Pubitemid 44742356)
12. Cuzin L, Delpierre C, Gerard S, et al. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. Clin Infect Dis. 2007;45:654-7. (Pubitemid 47328650)
13. Silverberg M, Leyden W, Horberg M, et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684-91.
14. Greenbaum A, Wilson L, Keruly J, et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS. 2008;22:2331-9.
15. Orchi N, Balzano R, Scognamiglio P, et al. Ageing with HIV: newly diagnosed older adults in Italy. Aids Care. 2008;20:419-25. (Pubitemid 351652489)
16. Stall R, Catania J. AIDS risk behaviors among late middle-aged and elderly Americans: the national AIDS behavioral surveys. Arch Intern Med. 1994;154:57-63. (Pubitemid 24018102)
17. Smith R, Delpech V, Brown A, et al. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS. 2010;24:2109-15.
18. Caro-Murillo A, Gil A, Navarro G, et al. La infección por VIH en diferentes grupos de edad: potenciales implicaciones para la prevención. [HIV infection in differing age groups: potential implications for prevention]. Cohorte CoRIS, España, 2004-2008. Med Clin (Barc). 2010;134:521-7.
19. Zingmond D, Kilbourne A, Justice A, et al. Differences in symptom expression in older HIV-positive patients: The Veterans Aging Cohort 3 site study and HIV cost and service utilization study experience. J Acquir Immune Defic Syndr. 2003;33:S84-92.
20. Casau N. Perspective on HIV Infection and Aging. Emerging Research on the Horizon. Clin Infect Dis. 2005;41:855-63.
21. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006;57:4-7. (Pubitemid 43057052)
22. Sabi T. AIDS, the new "great imitator". J Am Genatr Soc. 1987;35:460-4
23. Lindau S, Schumm L, Laumann E, et al. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357:762-74. (Pubitemid 47295643)
24. Centers for Disease Control and Prevention. AIDS among persons aged greater than or equal to 50 years - United States, 1991-1996 MMWR. 1998;47:21-7.
25. Sanders G, Bayoumi A, Holodniy M, et al. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148:889-903. (Pubitemid 351860821)
26. Goedert J, Kessler C, Aledort L, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989;321:1141-8. (Pubitemid 19255808)
27. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-29. (Pubitemid 34786200)
28. Gutiérrez F, Padilla S, Masiá M, et al. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy long-term follow-up of a multicenter cohort. PLOS One. 2008;1:e89.
29. Braithwaite R, Justice A, Chang C, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118:890-8. (Pubitemid 41097468)
30. Gutiérrez F, Padilla S, Masiá M, et al. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res. 2008;6:100-7. (Pubitemid 351479789)
31. Shah S, McGowan J, Smith S, et al. Comorbid conditions, treatment, and health maintenance in older persons with HIV infection in New York City. Clin Infect Dis. 2002;35:1238-43. (Pubitemid 35305872)
32. Sureka A, Parada J, Deloria-Knoll M, et al. HIV-related pneumonia care in older patients hospitalized in the early HAART era. AIDS Patient Care STDS. 2004;18:99-107. (Pubitemid 38240874)
33. Palella F, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34.
34. When To Start Consortium. Timing of initiation of antiretroviral 10 therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373;1352-63.
35. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262-70.
36. Yoshikawa T. Epidemiology and unique aspects of aging and infections. Clin Infect Dis. 2000;30:931-3. (Pubitemid 32250334)
37. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231-41. (Pubitemid 351160160)
38. Neuhaus J, Jacobs D, Baker J, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-95.
39. Grijsen M, Vrouenraets S, Steingrover R, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS. 2010;24:2233-8.
40. Grund B, Peng G, Gibert C, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519-29.
41. Le Maoult J, Szabo P, Weskler M. Effect of age on humoral immunity, selection of the B cell repertoire and B-cell development. Immunol Rev. 1997;160:115-26. (Pubitemid 28021371)
42. Vasto S, Colonna-Romano G, Larbi A, et al. Role of persistent CMV infection in configuring T cell immunity in the elderly. Immun Ageing. 2007;4:2.
43. Brenchley J, Karandikar N, Betts M, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101:2711-20. (Pubitemid 36857634)
44. Pawelec G, Akbar A, Caruso C, et al. Is immunosenescence infectious? Trends Immunol. 2004;25:406-10.
45. Levacher M, Hulstaert F, Tallet S, et al. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol. 1992;90:376-82. (Pubitemid 23001803)
46. Papagno L, Spina C, Marchant A, et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. Plos Biol. 2004;2:E20.
47. Barbour J, Ndhlovu L, Xuan Tan Q, et al. High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replication. PLoS One. 2009;4:e4408.
48. Franco J, Rubio A, Martinez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood. 2002;99:3702-6. (Pubitemid 34534541)
49. de la Rosa R, Leal M. Thymic involvement in immune recovery among chronic HIV-infected adults under highly active antiretroviral therapy. J Antimicrob Chemother. 2003;52:155-8. (Pubitemid 36986871)
50. Jiang W, Lederman M, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199:1177-85.
51. Molina-Pinelo S, Vallejo A, Diaz L, et al. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation. J Antimicrob Chemother. 2009;64:579-88.
52. Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-1 infected patients aged 60 years or older after 24 months of follow up. AIDS. 2001;15:1591-3. (Pubitemid 32744614)
53. Yamashita T, Phair J, Muñoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Mutanter AIDS. Cohort Study AIDS. 2001;15:735-46. (Pubitemid 32423221)
54. Goodkin K, Shapshak P, Asthana D, et al. Older age and plasma viral load in HIV-1 infection. AIDS. 2004;18(Suppl 1):S87-98.
55. Kalayjian R, Spritzler J, Pu M, et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis. 2005;192:1577-87. (Pubitemid 41504693)
56. Kaufmann G, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361-72. (Pubitemid 41022115)
57. Manfredi R, Chiodo F. A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS. 2000;14:1475-7. (Pubitemid 30459534)
58. Baker J, Peng G, Rapkin J, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr. 2008;48:541-6.
59. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS. 2008;22:1463-73.
60. Grimes R, Otiniano M, Rodriguez-Barradas M, et al. Clinical experience with HIV-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis. 2002;34:1530-3. (Pubitemid 34553714)
61. Manfredi R, Calza L, Cocchi D, et al. Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr. 2003;33:112-4. (Pubitemid 36547249)
62. Tumbarello M, Rabagliati R, de Gaetano D, et al. Older HIV-positive patients in the era of highly active antiretroviral therapy changing of a scenario. AIDS. 2003;17:128-31. (Pubitemid 36106310)
63. Navarro G, Nogueras M, Segura F, et al. HIV-1 infected patients older than 50 years. PISCIS cohort study. J Infect. 2008;57:64-71.
64. Brañas F, Berenguer J, Sânchez-Conde M, et al. The eldest of older adult living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med. 2008;121:820-4.
65. Carrieri M, Leport C, Protopescu C, et al. Factors associated with non-adherence to highly active antiretroviral therapy. A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr. 2006;41:477-85.
66. Barclay T, Hinkin C, Castellon S, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol. 2007;26:40-9. (Pubitemid 46072023)
67. D'Arminio A, Sabin C, Phillips A, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004;18:1811-7.
68. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy Results from the DAD study. AIDS. 2003;17:1179-93. (Pubitemid 36667761)
69. Friis-Møller N, Sabin C, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
70. DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35. (Pubitemid 46658704)
71. Obel N, Thomsen H, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625-31. (Pubitemid 46871511)
72. Grunfeld C, Delaney J, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23:1841-9.
73. Van Guilder G, Stauffer B, Mestek M, et al. HIV-1 infection is associated with accelerated vascular aging. Proceeding of the 16th CROI, Montreal, Canada; Feb 8-11, 2009 [abstract 731].
74. Grandominico J, Fichtenbaum C. Short-term effect of HAART on blood pressure in HIV-infected individuals. HIV Clin Trials. 2008;9:52-60. (Pubitemid 351214241)
75. Bernardino de la Serna J, Zamora F, Montes M, et al. Hypertension, HIV infection, and highly active antiretroviral therapy. Enferm Infecc Microbiol Clin. 2010;28:32-7.
76. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals. The Hawaii Aging with HIV-1 Cohort. Neurology. 2004;63:822-7.
77. Heaton R, Franklin D, Clifford D, et al. HIV-associated neurocognitive impairment remains prevalent in the era of combination ART: The CHARTER Study Proceeding of the 16th CROI, Montreal, Canada; Feb 8-11, 2009 [abstract 154].
78. Dulioust A, Lerolle N, Dolphin P, et al. High frequency of neurocognitive disorders in older HIV-infected patients despite a sustained virological and immunological response on cART: The Sigma Study Proceeding of the 16th CROI, Montreal, Canada; Feb 8-11, 2009 [abstract 459].
79. Ances B, Yeh J, Vaida F, et al. Additive effects of aging and HIV serostatus on cerebral blood flow. Proceeding of the 16th CROI, Montreal, Canada; Feb 8-11, 2009 [abstract 459].
80. Ciesla J, Roberts J. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725-30. (Pubitemid 32429839)
81. Olatunji B, Mimiaga M, O'Cleirigh C, et al. Review of treatment studies of depression in HIV. Top HIV Med. 2006;14;112-24.
82. Samet J, Phillips S, Horton N, et al. Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses. 2004;20:151-5. (Pubitemid 38280925)
83. Ances B, Vaida F, Rosario D, et al. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS. 2009;23:2317-22.
84. Ellis R, Rosario D, Clifford D, et al. Continued high prevalence and adverse clinical impact of HIV-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study Arch Neurol. 2010;67:552-8.
85. Clifford G, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-32. (Pubitemid 40528605)
86. Silverberg M, Abrams D. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007;19:446-51.
87. Silverberg M, Leyden W, Chao C, et al. Infection-related non-AIDS-defining cancer risk in HIV-infected and uninfected. Proceeding of the 16th CROI, Montreal, Canada; Feb 8-11, 2009 [abstract 30].
88. Pantanowitz L, Schlecht H, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol. 2006;18:469-78.
89. Long J, Engels E, Moore R, et al. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008;22:489-96. (Pubitemid 351317290)
90. Engels E. HIV infection, aging, and cancer. J Clin Epidemiol. 2001;54(Suppi 1):29-34.
91. Shiels M, Cole S, Kirk G, et al. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611-22.
92. Overton E, Mondy K, Bush T, et al. Factors associated with low bone mineral density in a large cohort of HIV-infected US adults: Baseline results from the SUN Study In: 14th CROI. February 24-28, 2007. Los Angeles, CA [abstract 836].
93. Arnsten J, Freeman R, Howard A, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21:617-23.
94. Bruera D, Luna N, David D, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17:1917-23. (Pubitemid 37070277)
95. Brown T, Qaqish R. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165-74. (Pubitemid 44684707)
96. Sharma A, Cohen H, Freeman R, et al. Prospective evaluation of bone mineral density among middle-ages HIV-infected women. Proceeding of the 16th CROI, Montreal, Canada; Feb 8-11, 2009 [abstract 757].
97. Short C, Shaw S, Fisher M, et al. Evaluation of peripheral dual energy x-ray absorptiometry as a tool for identification of low bone mineral density in HIV-infected men. Proceeding of the 16th CROI, Montreal, Canada; Feb 8-11, 2009 [abstract 753].
98. Crothers K, Butt A, Gibert C, et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006;130:1326-33. (Pubitemid 44786723)
99. Beck J, Rosen M, Peavy H. Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. Am J Resp Crit Care Med. 2001;164:2120-6. (Pubitemid 34020255)
100. Diaz P, King M, Pacht E, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med. 2000;132:369-72. (Pubitemid 30127775)
101. Lichtenstein K, Ward D, Moorman A, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15-1389-98.
102. Martinez E, Mocroft A, Garcia-Viejo M, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-8. (Pubitemid 32179612)
103. Mothe B, Perez I, Domingo P, et al. HIV-1 infection in subjects older than 70: a mutanter cross-sectional assessment in Catalonia, Spain. Curr HIV Res. 2009;7:597-600.
104. Effros R, Fletcher C, Gebo K, et al. Workshop on HIV infection and aging what is known and future research directions. Clin Infect Dis. 2008;47:542-53.
105. Fried L, Tangen C, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol. A Biol Sci Med SCI. 2001;56:M146-56.
106. Desquilbet L, Jacobson L, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med SCI. 2007;62:1279-86. (Pubitemid 350287617)
107. Walston J, McBurnie M, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med. 2002;162:2333-41. (Pubitemid 35332516)
108. Leng S, Yang H, Walston J. Decreased cell proliferation and altered cytokine production in frail older adults. Aging Clin Exp Res. 2004;16:249-52. (Pubitemid 39232497)
109. Rhee M, Greenblatt D. Pharmacologic consideration for the use of antiretroviral agents in the elderly. J Clin Pharmacol. 2008;48:1212-25.
110. Gebo K. HIV infection in older people. BMJ. 2009;338:1455-6.
111. Bressler R, Bahl J. Principles of drug therapy for the elderly patient. Mayo Clin Proc. 2003;78:1564-77.
112. Kim R, Fromm M, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-94. (Pubitemid 28067324)
113. Shelton M, Adams J, Hewitt R, et al. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Pharmacotherapy. 1997;17:438-44. (Pubitemid 27227550)
114. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67-76.
115. Boffito M, Back D, Blaschke T, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19;825-35.
116. Letendre S, Marquie-beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
117. Cysique L, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73:342-8.
118. Tozzi V, Balestra P, Salvatori M, et al. Changes in cognition during antiretroviral therapy comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52:56-63.
119. Sotaniemi E, Arranto A, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331-9.
120. George J, Byth K, Farrell G. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol. 1995;50:727-30.
121. Robertson S, Penzak S, Pau A. Drug interactions in the management of. HIV infection: an update. Expert Opin Pharmacother. 2007;8:2947-63.
122. Court M. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev. 2010;42:202-17.
123. Rowe J, Andres R, Tobin J, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155-63.
124. Gupta S, Eustace J, Winston J, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-85. (Pubitemid 40720806)
125. Guidelines for the Use of Antiretroviral Agents in HIV-1-lnfected Adults and Adolescents - December 1, 2009. Available in: http://www.aidsinfo.nih.gov/ Guidelines/GuidelineDetail-aspx?Menultem=Guidelines&Search= Off&GuidelineID=7&ClassID=1 [accessed Apr 16, 2010].
126. Documento de consensu del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultes infectados por el virus de la immunodeficiencia humana (Update January 2010). Available in: http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2010- DocconsensoTARGESIDA-PNS-verpc.pdf [accessed Apr 16, 2010].
127. Parsons T, Spritzler J, Stocker V, et al. The effect of age on lopinavir concentrations. Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City, Quebec, Canada [abstract 40].
128. Bertz R, Lam W, Hsu A, et al. Effects of gender, race, age and weight on the pharmacokinetics of lopinavir after single-dose Kaletra (lopinavir/ ritonavir) in healthy adult subjects Proceeding of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands; Apr 2-4, 2001 [abstract 3,11].
129. Gibbons S, Back D, Khoo S. Is there evidence of age-dependent variation in lopinavir or efavirenz levels in female subjects in a clinical setting? Proceeding of the 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada; Apr 28-30, 2005 [abstract 54].
130. O'Mara E, Randall D, Stoltz R, et al. BMS-232632: a prospective study of age and gender effects on single-dose pharmacokinetics in healthy volunteers. Proceeding of the 1st IASC on HIV Pathogenesis and Treatment, Buenos Aires, Argentina; Jul 8-11, 2001 [abstract 350].
131. Telenti A, Zanger UM. Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol. 2008;48:227-56. (Pubitemid 351738153)
132. Vidal F, Gutiérrez F, Gutierrez M, et al. Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Rev. 2010;12:15-30.
133. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment. Swiss HIV Cohort Study Lancet. 2001;358:1322-7. (Pubitemid 33016496)
134. Curkendall S, Richardson J, Emons M, et al. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2007;8:483-90. (Pubitemid 47616826)
135. Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108-16.
136. Zimmermann A, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions Clin Infect Dis. 2006;42:283-90.
137. Cespedes M, Aberg J. Neuropsychiatric complications of antiretroviral therapy. Drug Saf. 2006;29;865-74.
138. Cherry C, Affandi J, Imran D, et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology. 2009;73;315-20.
139. Gebo K, Moore R. Treatment of HIV infection in the older patient. Expert Rev Anti Infect Ther. 2004;2:733-43. (Pubitemid 39369055)
140. Gazzard B, Clumeck N, D'Arminio Monforte A, et al. Indicator disease-guided testing for HIV - the next step for Europe? HIV Med 2008;9(Suppl 2):34-40.
141. Branson B, Handsfield H, Lampe M, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17.
142. Qaseem A, Snow V, Shekelle P, et al. Screening for HIV in health care settings: A Guidance Statement From the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150:125-31.
143. UK National Guidelines for HIV Testing 2008. London: British HIV Association, British Association of Sexual Health and HIV and British Infection Society; 2008.
144. Aberg J, Kaplan J, Libman H, et al. Primary care guidelines for the management of persons infected with HIV: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America Clin Infect Dis. 2009;49:651-81.
145. Reinhold JP, Moon M, Tenner C, et al. Colorectal cancer screening in HIV-infected patients 50 years of age and older, missed opportunities for prevention. Am J Gastroenterol. 2005;100:1805-12. (Pubitemid 41648437)
146. Sheth A, Moore R, Gebo K. Provision of HIV and routine health maintenance in an urban HIV cohort. AIDS Patient Care STDS. 2006;20:318-25.
147. High K. Nutritional strategies to boost immunity and prevent infection in elderly individuals. Clin Infect Dis. 2001;33:1892-900. (Pubitemid 33105131)